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THE EUROPEAN GROUP ON ETHICS IN SCIENCE AND NEW TECHNOLOGIES (EGE), 
Having  regard  to  the  Treaty  on  European  Union  as  amended  by  the  Treaty  of 
Amsterdam,  and  in  particular  Article 6  (formerly  Article F)  of  the  common 
provisions,  and  the  new  Article  152  (formerly Article  129)  of the  EC  Treaty  on  public 
health,  and  in  particular paragraph 4(a)  referring to  substances of human origin; 
Having regard  to  Council Directive  89/381/EEC  of 14  June  1989  extending  the  scope 
of Directives  65/65/EEC  and  75/319/EEC  on  the  approximation  of provisions  laid 
down  by  law,  regulation  or  administrative  action  relating  to  proprietary  medicinal 
products  and  laying  down  special  provisions  for  medicinal  products  derived  from 
human blood or human plasma; 
Having regard to  Council Directive 76/768/EEC  of 27  July  1976  on  the  approximation 
of the  laws  of the  Member  States  relating  to  cosmetic  products,  and  in  particular  its 
6th amendment of 1993; 
Having  regard  to  Council  Directive  93/42/EEC  of  14  June  1993  concerning  medical 
devices,  and  the  proposal  of  19  April  1995  for  a  Directive  on  in  vitro  diagnostic 
medical devices  amending Directive 93/42/EEC; 
Having  regard  to  Directive  95/46/EC  of the  European  Parliament  and  of the  Council 
of  the  European  Union  of  24  October  1995  on  the  protection  of  individuals  with 
regard to  the processing of personal data and  on  the  free  movement of such  data; 
Having  regard  to  the  Resolution  of the  European  Parliament  on  prohibiting  trade  in 
transplant  organs  (A3-0074/93)  of  14  September  1993,  and  in  particular  point 2 
thereof,  which  calls  for  a ban  on  imports,  use  and/or  transplants  of organs  and  tissues 
whose origin  and  state  of health is  not known  with certainty; 
Having  regard  to  Recommendation  R(94)  1  of  the  Committee  of  Ministers  of  the 
Council of Europe on  Human Tissue Banks  adopted on  14  March  1994; 
Having  regard  to  Resolution  (78)  29  of the  Committee  of Ministers  of the  Council  of 
Europe on  harmonisation of legislation  of Member States  relating to  removal,  grafting 
and transplantation of human substances,  adopted on  11  May  1978; 
Having  regard  to  Recommendation  (79)  5  of  the  Committee  of  Ministers  of  the 
Council  of  Europe  to  Member  States  concerning  international  exchange  and 
transportation of human substances,  adopted  on  14  March  1979; Having  regard  to  the  Council  of  Europe  Convention  on  Human  Rights  and 
Biomedicine,  signed on 4 April  1997; 
Having  regard  to  the  Universal  Declaration  on  the  human  genome  and  the  rights  of 
man  adopted by the UNESCO  on  11  November  1997; 
Having  regard  to  the  various  laws  and  rules  applying  in  some  Members  States 
concerning human  tissues or organs; 
Having  regard  to  the  round-table  that  the  Group  organised  with  Members  of  the 
European  Parliament,  experts,  representatives  of  industry,  research,  professional 
associations  and  patients  on  27  November  1996,  and  to  the  hearing  of experts  and 
Commission departments  on  17  March  1998; 
Having heard the rapporteur Mr 0. Quintana-Trias, 
1.  WHEREAS: 
1.1  What are human tissues? 
Human tissue is  defined  as  a functional  group  of cells. 
For the  purposes  of this  Opinion,  human  tissues  means  constituent parts  of the  human  body 
such as:  bones,  skin,  heart valves,  cornea,  tendons,  arteries,  veins,  dura mater as  well  as  foetal 
tissues  obtained following  abortions,  placenta and  umbilical  cord  (the cord itself and  the  cells 
it contains). 
The  Opinion  also  covers  cells  intended  for  grafting  (in  particular  for  somatic  gene  therapy 
and  cell  therapy),  cell  lines  from  cell  cultures  as  well  as  cells  used  to  produce  proteins  and 
other substances  (e.g.  monoclonal antibodies). 
1.2  Parts and products of human origin not covered by this Opinion 
This  Opinion  does  not  cover  organs  for  transplantation,  which  are  already  covered  by 
comprehensive,  detailed national legislation in  all  Member States of the  European Union. 
Neither does  the Opinion cover: 
- blood and blood products,  which  are  currently  covered by national  rules  and  by Community 
rules pursuant to the  above-mentioned Directive of 14  June  1989; 
- hair,  nails,  breastmilk  and  body  waste  (urine,  sweat,  saliva),  which  are  treated  differently 
because their removal does  not give rise to  major ethical problems; 
- gametes,  reproductive  tissues  (such  as  ovaries)  and  embryos,  which  are  covered by  specific 
national rules  and give rise to  quite  specific ethical problems. 
Every  stored  tissue  is  a  potential  source  of  genetic  information  (DNA).  However,  this 
Opinion does not cover genomic banks (DNA banks or "biobanks"), which give rise to  many 
important  legal  and  ethical  questions  (particularly  as  regards  the  confidentiality  of data, 
access  to  such  data,  and  possible  uses  even  in  the  very  long  term).  The  Group  intends  to 
consider these in a subsequent Opinion. 
2 1.3  Various uses of tissues 
This  Opinion covers  a wide  variety of human  tissues,  which can be used  for  a wide  variety of 
purposes: 
- for  diagnostic  purposes:  e.g.  to  determine  whether  a tumour is  cancerous  or not by  removing 
tissue  (biopsy).  In  order  to  establish  the  cause  of  death,  forensic  medicine  also  analyses 
human  tissues.  Likewise,  human  tissues  are  the  subject  of toxicological  studies  to  test  the 
effects  on  them of certain products:  insecticides, cosmetics,  medicines; 
- for  therapeutic  purposes:  in  this  case,  tissues  are  mostly  used  for  transplantation.  For 
example,  orthopaedic  surgery uses  fragments  of bone,  while  skin  grafts  are  used  to  treat  bum 
victims  or  as  dressings  in  the  treatment  of  diabetics.  Tissues  are  also  used  as  sources  of 
proteins  or  other  therapeutic  substances.  Today  they  are  only  very  rarely  used  as  sources  of 
hormones in the  European  Union; 
- for  research  purposes:  basic,  epidemiological  and  clinical  research.  Such  research  has,  for 
example, made it possible  to  establish a link between asbestos  and  a lung cancer. 
Nevertheless,  tissues  may  no  longer  be  used  to  make  non-medicinal  products.  The  use  of 
human  tissues  in  the  manufacture  of  cosmetics  was  banned  in  Europe  by  the  above-
mentioned  Directive  on  the  approximation  of  the  laws  of  the  Member  States  relating  to 
cosmetic  products  of  1976,  which  was  amended  in  1995,  and  applies  in  this  respect  from 
30 June  1997.  The  Directive  gives  as  grounds  for  the  ban  the  risk  of  transmission  of 
"Creutzfeldt-Jakob disease, human spongiform encephalopathy, and certain viral diseases". 
1.4  Origin and removal of tissues 
The most common source  of human tissue is  removal from  the body  as  part of diagnosis  or 
treatment. It may be affected tissues or surplus tissues, mainly surgical residues. 
Tissues  are  also  frequently  removed from  dead  donors.  Other sources  include foetal  tissues 
obtained  following  abortions  (spontaneous  or  induced),  as  well  as  placenta  and  umbilical 
cords obtained at childbirth. 
Exceptionally, tissues may also be obtained from healthy volunteers (skin, for example). 
Tissues  are  generally  removed  or  obtained  in  health  care  institutions  or  medical  analysis 
laboratories. 
3 1.5  Tissue banks 
Unlike organs,  which cannot be conserved,  tissues  can easily be stored for  long periods.  Once 
removed  or  collected,  tissues  are  subject  to  a  series  of operations  which,  particularly  when 
they are  intended for transplantation,  comprise the following  functions: 
processing 
preserving and  storage 
registration  (to  collect the data which will enable in  particular the  source of the  tissues 
to  be  traced) 
distribution and  delivery. 
These are the functions performed by "tissue banks". Tissue banks are units or services which 
may be operated by public  or private,  profit-making or non-profit-making bodies  (hospitals, 
blood transfusion centres, and even, in some cases, large laboratories  ...  ). 
At  present  there  is  insufficient  information  on  tissue  storage  and  distribution  conditions 
across Europe, as  no general inventory of human tissue banks has been made. 
1.6  Processing of tissues 
The processing of tissues  is  primarily intended to  enable them to be preserved and  stored in 
tissue  banks.  Where  the  tissues  are  intended  for  transplantation  into  another  person, 
processing  also  includes  clinical,  microbiological  and  immunological  tests  intended  to 
safeguard the  safety of the recipient.  These tests  are  intended to  prevent the transmission  of 
infectious, neoplastic (cancer) and immunological diseases. 
Tissues  collected for  diagnostic  or research  purposes  are  generally  studied  in  their  original 
state in order to identify the illness affecting them. 
Products  can  also  now  be  obtained  by  increasingly  sophisticated  techniques  which  enable 
certain  properties  of  the  tissues  to  be  modified.  To  that  end  the  tissues  undergo  prior 
processing. This is the case in particular for  skin cultures, which enable large areas skin to be 
made available for grafting. 
1. 7  Distribution of tissues 
It  is  the function  of tissue  banks  to  organise  the  distribution  of tissues  to  the  professionals 
who will be using them for various purposes. 
1.8  Main ethical issues 
Wherever  tissues  are  removed  from  human  beings,  and  possibly  transplanted  into  other 
human beings,  the activities  involved in  the collection and use of such tissues are  subject to 
ethical  requirements  intended  to  safeguard  respect  for  human  beings,  their  dignity  and 
autonomy, and for the common good. 
4 The  issue  of  safety  is  also  vital,  as  the  European  Union  has  set  itself  the  objective  of 
guaranteeing  each  citizen  a  "high  level  of human  health  protection".  This  protection  must 
extend  to  tissue  donors  and  recipients,  and  to  all  health  care  professionals  - whose  work 
involves collecting, manipulating and using human tissues. 
At present we  cannot be sure that the health safety of tissues  is  properly ensured throughout 
the European Union. This is  due to the shortcomings of the existing national rules. As  a result 
tissues  move  freely  within  Europe  and  are  sometimes  even  imported  from  non-member 
countries, in many cases without detailed information on  their origin,  and in particular on the 
state of health of the donor. 
1.9  Protection of the donor and the recipient 
With regard to  the removal  of tissues,  the  main  ethical principles from  the  donor's point of 
view are: 
respect for the human body, even after the person's death; 
respect for the autonomy of the donor; thus, tissue may not be removed whenever the 
person refuses.  For deceased persons, this  implies that tissues may not be removed if 
the person refused consent during her/his lifetime; 
protection of vulnerable people, namely people unable to give consent; 
respect for private life and medical confidentiality, which is a fundamental right; 
the right to prior information on the conditions of removal and the expected use of the 
tissues; 
the  right  not  to  be  subjected  to  unfair  discrimination,  which  could  result  from  the 
revelation  of  data  collected  from  the  donor,  or  the  family,  to  third  parties  (e.g. 
employers and insurance companies). 
The main principles affecting recipients of allografts are: 
respect for the autonomy of the person concerned, which requires clear information on 
the risks and advantages of the proposed transplant; 
respect  for  private  life  and  medical  confidentiality,  which  applies  to  all  medical 
treatment; 
the  right  to  safety,  which requires  prior  verification  of the  quality  and  safety  of the 
tissue to be transplanted with regard to  the risk of transmission of infectious diseases, 
neoplasms and immunological diseases; 
the right of patients to  have  fair  access  to  the  therapeutic possibilities  offered by the 
transplantation of human tissues;  the effectiveness of this  right depends partly on the 
greater or lesser availability of tissues. 
5 1.10  The problem of commercialisation of human tissues 
All  Member  States  of the  European  Union  adhere  to  the  principle  that  donations  of human 
tissues  must  be  free,  following  the  example  of blood,  and  this  rules  out  any  payment  to  the 
donor.  However,  the  donor  may  receive  compensation  for  the  constraints  associated  with 
tissue removal  (e.g.  travel  expenses,  loss  of earnings,  etc.).  Some parties  maintain  that for  the 
sake of fairness,  when  the  tissues  become even  indirectly a  source of profit,  donors  should be 
paid.  Furthermore,  donor's  remuneration  might  increase  the  supply  of  tissues.  So  far, 
however,  the  arguments  in  favour  of  the  altruistic  nature  of  tissue  donation  (like  organ 
donation)  have prevailed.  They are  based on a regard for  solidarity.  Also  they  are  inspired by 
the  desire  to  avoid  the  human  person  being  regarded  as  an  object  (a  source  of organs  and 
tissues).  Another  argument  in  favour  of free  donations  is  to  avoid  all  risk  of exploitation  of 
the  most underprivileged  who  might be  led,  in  doubtful  conditions  of health,  to  donate  tissue 
exclusively or primarily for  financial reasons. 
As  an  example,  a debate arose  a few  years  ago  in the  United States with regard to  the removal 
of tissues  from  an  individual  whose  cells  had  rare  features  (the  Moore  case).  These  tissues, 
ostensibly removed  as  part of a medical  treatment,  had  in  reality enabled profitable  industrial 
applications,  and this  information  was  withheld  from  the  donor.  The  deficient and misleading 
information  given  to  the  donor  was  condemned  by  the  Court,  even  though  the  judge  did  not 
accept  that  Moore  should  participate  in  the  economic  benefit  derived  from  the  use  of these 
tissues.  However,  this  case  leads  some  commentators  to  call  for  payments  to  be  made  to 
tissue donors  for  the  sake of equity. 
The issue of the commercialisation of human tissues  which have been  processed and  prepared 
for  therapeutic purposes is  even more controversial. 
For  some,  tissue  banks  must  be  operated  only  by  non-profit-making  bodies,  as  the  tissues 
have originally been obtained free  of charge in  a spirit of altruism. 
For others  hold that the processing and conversion of tissues  involve costs  which they believe 
justify their commercial  sale,  in  the  same  way  as  blood derivatives.  The commercialisation of 
human  tissues  has  the  added  advantage,  according  to  its  proponents,  of encouraging  industry 
to  invest  in  areas  which  will  result  in  greater  availability  of  tissues  on  the  market.  This 
argument is  most often  advanced with regard to  "engineered" tissues requiring  sophisticated 
industrial processing techniques. 
Currently, although no  surveys of tissue banks in Europe have been carried out, it seems that 
most  of the  banks  are  non  profit,  nevertheless  some  of them  have  been  set  up  by  private 
industries, particularly for the production of engineered tissues. 
* * * * * * * * * 
6 2.  IN  THIS  CONTEXT,  AND  IN  VIEW  OF  THE  URGENT  NEED  TO  REGULATE  THE 
CONDITIONS UNDER WHICH HUMAN TISSUES CIRCULATE WITHIN THE EUROPEAN MARKET, 
THE GROUP SUBMITS THE FOLLOWING OPINION: 
2.1  Ethical imperative to protect health 
No  substance  of human  origin  is  free  from  the  risk  of disease  transmission.  Thus  tissues,  in 
particular  those  intended  for  transplantation  to  third  parties  or  for  the  preparation  of 
pharmaceutical  specialities,  must  undergo  advance  testing  to  provide  maximum  health 
guarantees in  accordance  with the  state of the art. 
To this  end,  the health  safety rules to  be  drawn  up  at  Community level must at least comprise: 
*  research  on  the  personal,  medical  and  family  history  of the  donor  in  order  to  detect  all 
possible transmissible diseases  (e.g.  to  ascertain  any  occurrence in  the  donor of a  subacute 
spongiform  encephalopathy  - Creutzfeldt-Jakob  disease  for  which  no  valid  test  on  living 
donors exists  or a state  of dementia before death that could be  a symptom of this  disease); 
*  thorough  biological  analyses  according  to  recommendions  of  good  medical  practice  in 
order  to  detect,  for  example,  HN  viruses  and,  more  generally,  transmissible  infectious 
diseases; 
*  any  additional  analyses  that  may  be  necessary  in  view  of the  donor's  history  or of the 
nature of the tissue in question. 
The  use  of  certain  types  of  tissue  for  allografts  or  as  a  basis  for  the  production  of 
pharmaceutical substances  should be banned or at least limited.  This  includes tissues  whose 
safety  cannot  be  proved  due  to  the  absence  of valid  tests  (dura  mater,  auditory  ossicles, 
tympanic and petrosal tissue used for grafting.) 
Tissue retrieval should be supervised by a physician. In  addition, all tissue procurement must 
be carried out by qualified staff under strict conditions (in particular, licensed premises which 
meet technical health standards). 
The  conduct  of the  necessary  tests  must  be  supplemented  by  surveillance  mechanisms  to 
detect  any  accidents  and  their  origin  at  the  earliest  possible  stage:  donor  documentation, 
monitoring  of recipients,  registers  of accidents  and  remedial  procedures  in  place.  Such  a 
surveillance and traceability system should be an  integral part of the health rules drawn up  at 
Community level. 
The  establishment  of  a  European  structure  for  the  protection  of  health  should  also  be 
envisaged,  in  collaboration  with  the  European  Agency  for  the  Evaluation  of  Medicinal 
Products. 
2.2  Body integrity 
The  integrity of the  human  body  should  be  ensured  when  procuring  human  tissue  from  an 
individual, living or dead. When tissues are procured from the deceased, due regard should be 
paid for the feelings of relatives. 
7 2.3  Information and consent 
The  procurement  of  human  tissues  requires,  as  a  principle,  the  prior,  informed  and  free 
consent  of  the  person  concerned.  This  does  not  apply  in  the  case  of  tissue  procurement 
ordered by a judge in  the context of judicial, in  particular criminal, proceedings. 
While  consent  is  a  fundamental  ethical  principle  in  Europe,  the  procedures  involved  and 
forms  of such  consent  (oral  or in  writing,  before  a  witness  or not,  explicit  or presumed,  etc.) 
are  a matter for  national legislation based on  the  legal traditions  of each country. 
2.3.1  Living donors 
In  order to be informed, the donor's consent must have been given on the basis of information 
provided  in  as  clear  and  precise  lay  terms  as  possible  by  the  doctor  supervising  the 
procurement. 
The information provided to the donor should concern: 
*  the procurement arrangements, in particular concerning the free nature of the donation, and 
the extent of its anonymity. 
*  possible  tissue  storage  time  and  conditions,  and  conditions  of registration  of  data  in 
databases,  in  conformity  with  requirements  of  private  life  protection  and  medical 
confidentiality; 
*  foreseeable  use  of the  tissues  (diagnostic,  allograft or autograft,  pharmaceutical products, 
research,  production  of cellular lines  for  various  uses,  etc.).  The donor  may at  any  time 
withdraw her/his consent. 
2.3.2  Deceased donors 
Consent of a donor for retrieval of tissues after death may take different forms  depending on 
the national systems ("explicit" or "presumed" consent). However, no retrieval of tissues may 
take  place,  with  the  exception  of judicial  proceedings,  if  the  party  concerned  formally 
objected while alive.  Furthermore, if there has been no  expression of will  and the applicable 
system is  that of "presumed" consent, doctors must ensure as  far  as  possible that relatives or 
next of kin have the opportunity to express the deceased person's wishes, and must take these 
into account. 
2.3.3  Special cases 
Special provision must be made in the following three cases: 
•  Foetal tissue procured after an abortion 
No  abortion  should  be  induced  for  the  purpose  of obtaining  foetal  tissue.  In  the  case  of 
deliberate or spontaneous abortion, the retrieval of the tissue requires the specific free  and 
informed consent of the  woman  and,  where  appropriate,  of the couple.  The timing  of the 
termination and the way in  which it is carried out must not be influenced by the retrieval of 
the tissues. 
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•  Placenta and umbilical cord procured during  delivery 
The  placenta  can  be  an  important  source  of  vessels  for  transplant  purposes.  In  these 
conditions,  its procurement must be  subject to  prior information to  the  woman. 
Umbilical  cord  may  increasingly  be  procured  because  of its  therapeutic  interests.  Umbilical 
cord blood  banks  are  already  being  set  up.  The  hematopoietic  stem  cells  in  the  cord  blood 
may  be  useful,  for  example  in  the  case  of leukaemia,  for  autografts  or  allografts.  In  this 
respect,  the  information  provided to  the  woman  or to  the  couple  must  clearly explain  these 
prospective new treatments, but stress that they are still very much at the experimental stage. 
•  Surgical residues 
Surgical residues are currently one of the  major source of tissues for allografts.  Nonetheless, 
their procurement during operations (e.g.  head of the  femur,  in the course of hip  operations) 
is frequently unregulated. 
The provision of information to the donor is all the more necessary today as  the tests to verify 
the safety of the tissues can only be carried out with the consent of the donor. 
2.4  Respect of privacy and protection of the confidentiality of information collected 
during tissue procurement 
In  the  interests  of anonymity,  it is  prohibited to  disclose  information that could identify the 
donor,  and  the recipient.  In  general,  the donor should not know  the  identity of the recipient, 
nor should the recipient know the identity of the donor. 
Procurement  and  storage  of tissues  in  tissue  banks  leads  to  the  collection  and  storage  of a 
growing number of personal and family data.  This is  the case,  for example, when tissues  are 
stored following analysis for diagnostic purposes. It is also the case when tissues are removed 
for  use  in  allografts,  for  health  reasons.  In  the  event  of  subsequent  sanitary  or  health 
problems,  there  is  a  need  to  find  the  donor's  identity  and  the  medical  file  (traceability 
requirement). 
In  order to  reconcile the  traceability requirement  and  the need  to  protect the  donor's  rights 
(medical  confidentiality and  privacy),  tissue  banks  must take  the  necessary  steps  to  protect 
confidentiality of the data by developing appropriate coding systems. 
2.5  Preventing possible discrimination 
As  with all health information, personal data relating to  tissues stored by tissue banks may be 
the  cause  of unwarranted discrimination if revealed to  third  parties  (in  particular employers 
and  insurance companies).  Tissue banks must therefore take all  appropriate  steps  to  prevent 
misuse of the personal data at their disposal. 
9 .· 
2.6  Promoting solidarity and tissue availability in Europe 
Anonymous  and  free  tissue  donation  - like  organ  donation  - basically remains  a  voluntary act 
of solidarity.  Therefore  it is  necessary in each  Member State  and  at  European  Union  level  to 
encourage  people  to  donate  tissue  as  an  act  of solidarity.  To  this  end,  public  should  be  given 
clear information  on  the  conditions  under  which  the  donated  tissues  will  be  used  and  on  the 
likely  public  health  benefits.  The  information  in  question  must  also  stress  the  specific 
responsibility of the  tissue  banks with regard to  the  safeguarding of ethical principles. 
2. 7  Role and responsibilities of the tissue banks 
Activities  of procurement,  which  are  non-commercial,  as  well  as  activities  carried  out  by 
tissue  banks  require  an  authorisation.  This  authorisation  must  be  subject  to  compliance  with 
basic  ethical  principles  and  with  health  safety  standards,  which  themselves  are  an  ethical 
imperative.  Safety rules  must be uniform throughout the European Union. 
Tissue  banks  have  an  eminent  responsibility  to  monitor  implementation  of these  rules  and 
principles.  They  should  refuse  to  accept  tissues  the  procurement  of which  does  not  satisfy 
ethical principles and safety rules. 
Tissue banks  also  have  specific responsibilities  as  regards  protecting the  confidentiality of the 
personal data they keep  on  donors  and  their families. 
In  view  of their  responsibility  for  the  quality  and  safety  of the  tissues  they  provide  to  third 
parties,  banks  should  be  obliged  to  keep  a  register  of the  tissues  stored  and  distributed.  This 
register should be  available  for  presentation to  the national inspectorates  at all  times. 
2.8  Profit or non-profit tissue banks 
In  principle,  tissue  bank  activities  should  be  reserved  to  public  health  institutions  or  non-
profit-making  organisations.  In  such  case,  this  means  that  the  delivery  price  of the  tissues 
only covers the bank's expenses relating to the tissues in question. 
Nevertheless,  given  the  current  state  of development  of the  sector,  it is  difficult to  exclude 
tissue banking activities by commercial organisations, such as  large private laboratories. This 
is  particularly  true  where  human  tissues  are  used  as  a  basis  for  "engineered"  products 
requiring the use of sophisticated medical techniques. Tissue banks set up by industry should 
be subject to the same licensing and monitoring requirements as non-commercial operators. 
2.9  Towards equitable access to the therapeutic opportunities presented by the use 
of human tissues 
The medical use of products of human origin is inevitably constrained by limited availability, 
owing to  the precautions that have to be taken to  guarantee safety and to the voluntary nature 
of donations. 
10 .. 
According to  the  principle  of justice, it is  necessary to  define  the  criteria for  priority access  to 
such  tissue  products  in  the  most  transparent  manner  possible,  on  the  basis  of an  objective 
evaluation  of  medical  needs,  taking  into  consideration  the  objectives  for  public  health  in 
Europe. 
2.10  Tissue imports from outside the European Union 
Tissue  imports  or  exports  should  be  licensed  by  Public  authorities.  Authorisation  should  be 
subject to  at least equivalent ethical and  health rules to those outlined above. 
2.11  Community survey on tissue banks 
The  European  Union  should  promote  periodic  surveys  in  the  Member  States  to  obtain  and 
diffuse  data  on  practices  relating  to  human  tissues,  from  procurement  to  distribution,  the 
organisation  of tissue  banks,  particularly  concerning  the  profit-making  or  non-profit  making 
aspect and  the  true dimension  of imports and  import controls. 
These  surveys  should  be  used  to  provide  better  information  to  the  public  on  the  ethical  and 
safety controls  in place,  as  well  as  on  perspectives  in  therapy,  diagnosis  and  research  offered 
by  uses  with human tissues. 
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